Pharmacotherapeutic management of atopic keratoconjunctivitis

References

• Rigoli L, Briuglia S, Caimmi S, et al. Gene-environment interactions in childhood asthma. Int J Immunopathol Pharmacol. 2011;24:41–47.
   PubMed Web of Science ®Google Scholar
• Pawankar R, Canonica GW, Holgate ST, et al. white book on allergy 2011–2012 executive summary. 2. World Allergy Organization. 2011 [cited 2019 Dec 11]. http://www.worldallergy.org
   Google Scholar
• Friedlaender MH. Ocular allergy. Curr Opin Allergy Clin Immunol. 2011 Oct;11(5):477–482.
   PubMed Web of Science ®Google Scholar
• Bielory L, Frohman L. Allergic and immunologic disorders of the eye. J Allergy Clin Immunol. 1992 Jan;89(1 Pt 1):1–15.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Applebaum DS, Sun GS, et al. Atopic keratoconjunctivitis: a review. J Am Acad Dermatol. 2014;70(3):569–575.
   PubMed Web of Science ®Google Scholar
• Hogan MJ. Atopic keratoconjunctivitis. Am J Ophthalmol. 1953;36(71):937–947.
   PubMedGoogle Scholar
• Calonge M, Herreras JM. Clinical grading of atopic keratoconjunctivitis. CurrOpin Allergy Clin Immunol. 2007;7:442–445.
   Web of Science ®Google Scholar
• Tuft SJ, Kemeny DM, Dart JK, et al. Clinical features of atopic keratoconjunctivitis. Ophthalmology. 1991;98:150–158.
   PubMed Web of Science ®Google Scholar
• Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2010;10:478–485.
   PubMed Web of Science ®Google Scholar
• Bielory B, Bielory L. Atopic dermatitis and keratoconjunctivitis. Immunol Allergy Clin North Am. 2010;30(3):323–336.
   PubMed Web of Science ®Google Scholar
• Ridolo E, Kihlgren P, Pellicelli I, et al. Atopic Keratoconjunctivitis: pharmacotherapy for the Elderly. Drugs Aging. 2019 Jul;36(7):581–588.
   PubMed Web of Science ®Google Scholar
• Sharma N, Rao K, Maharana PK, et al. Ocular allergy and keratoconus. Indian J Ophthalmol. 2013 Aug;61(8):407–409.
   PubMed Web of Science ®Google Scholar
• Polido JG, Cabral T, Perini Pde R, et al. Correlations between allergen-specific IgE serum levels in patients with ocular allergy. Cornea. 2015;34(9):1092‐1097.
   PubMed Web of Science ®Google Scholar
• Bonini S. Atopic keratoconjunctivitis. Allergy. 2004;59(Suppl.78):71–73.
   PubMedGoogle Scholar
• Matsuda A, Okayama Y, Terai N, et al. The role of interleukin-33 in chronic allergic conjunctivitis. Invest Ophthalmol Vis Sci. 2009;50:4646–4652.
   PubMed Web of Science ®Google Scholar
• Uchio E, Ono SY, Ikezawa Z, et al. Tear levels of interferon-gamma, interleukin (IL)-2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin Exp Allergy. 2000;30:103–109.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Borghesan F, Faggian D, et al. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol. 2000;129:151–158.
   PubMed Web of Science ®Google Scholar
• Calder VL, Jolly G, Hingorani M, et al. Cytokine production and mRNA expression by conjunctival T-cell lines in chronic allergic eye disease. Clin Exp Allergy. 1999;29:1214–1222.
   PubMed Web of Science ®Google Scholar
• Leonard JN, Dart JK. Chapter 67: the skin and the eyes. In: Burns T, Breathnach S, Cox N, et al., editors. Rook’s textbook of dermatology. Oxford: Wiley-Blackwell; 2010.
   Google Scholar
• Easty D, Entwistle C, Funk A, et al. Herpes simplex keratitis and keratoconus in the atopic patient: a clinical and immunological study. Trans Ophthalmol Soc U K. 1975;95(2):267–276.
   PubMedGoogle Scholar
• Power WJ, Tugal-Tutkun I, Foster CS. Long-term follow-up of patients with atopic keratoconjunctivitis. Ophthalmology. 1998;105:637–642.
   PubMed Web of Science ®Google Scholar
• Ibrahim OM, Matsumoto Y, Dogru M, et al. In Vivo confocal microscopy evaluation of meibomian gland dysfunction in atopic-keratoconjunctivitis patients. Ophthalmology. 2012 Oct;119(10):1961–1968.
   PubMed Web of Science ®Google Scholar
• Bowling B. Kanski’s clinical ophthalmology: a systematic approach. Eighth ed. Edinburgh: Elsevier Limited; 2016.
   Google Scholar
• Avunduk AM, Tekelioglu Y, Turk A, et al. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivitis: A 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin Ther. 2005;27:1392–1402.
   PubMed Web of Science ®Google Scholar
• Johnson HG, White GJ. Development of new antiallergic drugs (cromolyn sodium, lodoxamide tromethamine). What is the role of cholinergic stimulation in the biphasic dose response? Monogr Allergy. 1979;14:299‐306.
   PubMedGoogle Scholar
• Schmid KL, Schmid LM. Ocular allergy: causes and therapeutic options. Clin Exp Optom. 2000;83:257–270.
   PubMedGoogle Scholar
• Shaker M, Salcone E. An update on ocular allergy. Curr Opin Allergy Clin Immunol. 2016;16(5):505–510.
   PubMed Web of Science ®Google Scholar
• Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin Pharmacother. 2004;5:1979–1994.
   PubMed Web of Science ®Google Scholar
• Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol. 1998;81:211–218.
   PubMed Web of Science ®Google Scholar
• Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol. 1999;117(5):643–647.
   PubMedGoogle Scholar
• Bielory L, Schoenberg D. Emerging therapeutics for ocular surface disease. Curr Allergy Asthma Rep. 2019;19(3):16.
   PubMed Web of Science ®Google Scholar
• Manzouri B, Flynn TH, Larkin F, et al. Pharmacotherapy of allergic eye disease. Expert Opin Pharmacother. 2006;7:1191–1200.
   PubMed Web of Science ®Google Scholar
• Ridolo E, Montagni M, Bonzano L, et al. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy. 2015;13(1):1.
   PubMedGoogle Scholar
• Korenfeld MS, Silverstein SM, Cooke DL, et al. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009;35:26–34.
   PubMed Web of Science ®Google Scholar
• Hyvarinen L. Local treatment of allergic conjunctivitis. Duodecim. 1982;98:717–719.
   PubMedGoogle Scholar
• Foulds WS, Greaves DP, Herx-Heimer H, et al. Hydrocortisone in treatment of allergic conjunctivitis, allergic rhinitis, and bronchial asthma. Lancet. 1955;268:234–235.
   PubMedGoogle Scholar
• Comstock TL, Sheppard JD. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opin Pharmacother. 2018 Mar;19(4):337–353.
   PubMed Web of Science ®Google Scholar
• Bielory L. Ocular allergy guidelines: a practical treatment algorithm. Drugs. 2002;62(11):1611-34.
   PubMed Web of Science ®Google Scholar
• Flammiger A, Maibach H. Drug dosage in the elderly: dermatological drugs. Drugs Aging. 2006;23(3):203–215.
   PubMed Web of Science ®Google Scholar
• Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord. 1983;5(4):319–332.
   PubMed Web of Science ®Google Scholar
• Hall RC, Popkin MK, Stickney SK, et al. Presentation of the steroid psychoses. J Nerv Ment Dis. 1979;167(4):229–236.
   PubMed Web of Science ®Google Scholar
• Weinstein RS. Clinical practice: glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62–70.
   PubMed Web of Science ®Google Scholar
• Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Int Med. 2002;17(9):717–720.
   PubMed Web of Science ®Google Scholar
• Attas-Fox L, Barkana Y, Iskhakov V, et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res. 2008;33:545–549.
   PubMed Web of Science ®Google Scholar
• Ezeamuzie CI. Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. Int J Immunopharmacol. 1996;18:263–270.
   PubMed Web of Science ®Google Scholar
• González-López JJ, López-Alcalde J, Morcillo LR, et al. Topical cyclosporine for atopic keratoconjunctivitis. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009078.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology. 2004;111:476–482.
   PubMed Web of Science ®Google Scholar
• Daniell M, Constantinou M, Vu HT, et al. Randomized controlled trial of topical cyclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol. 2006;90:461–464.
   PubMed Web of Science ®Google Scholar
• Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25:365–372.
   PubMed Web of Science ®Google Scholar
• Ciclosporin eye preparations fact sheet [Internet]. Moorfields eye hospital; 2019 Sept 16 [cited 2019 Dec 11]. https://www.moorfields.nhs.uk/sites/default/files/Ciclosporin%20eye%20preparations%20fact%20sheet%20v2.0.pdf.
   Google Scholar
• Parvizi S, Muthusamy K, Hingorani M, et al. Topical ciclosporin 1 mg/ml for chronic ocular surface inflammation in children. Eye. 2018;32:1290–1291.
   PubMed Web of Science ®Google Scholar
• Al-Amri AM. Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis. Am J Ophthalmol. 2014 Feb;157(2):280–286.
   PubMed Web of Science ®Google Scholar
• Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology. 2008;115(6):988–92.e5.
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan T, Prisant O, Hannouche D, et al. Systemic cyclosporine A in severe atopic keratoconjunctivitis. Ophthalmology. 1997;104(8): 1300–1305. you have this reference twice, as 46 and 49.
   PubMed Web of Science ®Google Scholar
• Stumpf T, Luqmani N, Sumich P, et al. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea. 2006;25(10):1147–1149.
   PubMed Web of Science ®Google Scholar
• Anzaar F, Gallagher MJ, Bhat P, et al. Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis. Cornea. 2008;27(8):884–888.
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–432.
   PubMed Web of Science ®Google Scholar
• Gangaputra S, Newcomb CW, Liesegang TL. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–2198.
   PubMed Web of Science ®Google Scholar
• Hornbeak DM, Thorne JE. Immunosuppressive therapy for eye diseases: effectiveness, safety, side effects and their prevention. Taiwan J Ophthalmol. 2015;5(4):156–163.
   PubMedGoogle Scholar
• Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010;24:317–328.
   PubMed Web of Science ®Google Scholar
• Clark D; Paul Gomes; David Hollander, et al. The ALLEVIATE phase 3 allergic conjunctivitis clinical trial of topical ocular reproxalap, a novel RASP inhibitor. Poster presented at American Academy of Ophthalmology 2019 Meeting; October 12–15, 2019; San Francisco, CA. Abstract PO095.
   Google Scholar
• Study evaluating the efficacy and safety of PRT-2761 for the treatment of acute and chronic allergic conjunctivitis. Clinicaltrials.gov. cited 2018 Dec 26. Available from: https://clinicaltrials.gov/ct2/show/NCT03320434
   Google Scholar
• Jauhonen HM, Laihia J, Oksala O, et al. Topical cis-urocanic acid prevents ocular surface irritation in both IgE—independent and—mediated rat model. Graefes Arch Clin Exp Ophthalmol. 2017;255:2357–2362.
   PubMed Web of Science ®Google Scholar
• Jauhonen HM, Kari E, Pylkkanen L, et al. A randomized phase I clinical study of cisurocanic acid eye drops in healthy adult subjects. Acta Ophthalmol. 2015;93:368–376.
   PubMed Web of Science ®Google Scholar
• Dattoli SD, Baiula M, De Marco R, et al. DS-70, a novel and potent alpha4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs. Br J Pharmacol. 2018;175:3891–3910.
   PubMed Web of Science ®Google Scholar
• Guzman M, Sabbione F, Gabelloni ML, et al. Restoring conjunctival tolerance by topical nuclear factor-kappaB inhibitors reduces preservativefacilitated allergic conjunctivitis in mice. Invest Ophthalmol Vis Sci. 2014;55:6116–6126.
   PubMed Web of Science ®Google Scholar
• Lee HS, Kwon JY, Joo CK. Topical administration of beta-1,3- glucan to modulate allergic conjunctivitis in a murine model. Invest Ophthalmol Vis Sci. 2016;57:1352–1360.
   PubMed Web of Science ®Google Scholar
• Kwon JY, Lee HS, Joo CK. TRPV1 antagonist suppresses allergic conjunctivitis in a murine model. Ocul Immunol Inflamm. 2018;26:440–448.
   PubMed Web of Science ®Google Scholar
• Joint Formulary Committee. The British National formulary. 76th ed. London: BMJ Group and Pharmaceutical Press; 2018.
   Google Scholar